LFSC - ETF AI Analysis
Top Page
F/M Emerald Life Sciences Innovation ETF (LFSC)
Rating:52Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains so far this year and over the past month, indicating positive recent momentum.
Top Holdings With Strong Gains
Several of the largest positions, such as Spyre Therapeutics, Nektar Therapeutics, Mirum Pharmaceuticals, and United Therapeutics, have delivered strong year-to-date performance that supports the fund’s returns.
Focused Exposure to Health Care Innovation
With most of its assets in health care companies, the ETF gives investors targeted access to life sciences and medical innovation.
Negative Factors
High Sector Concentration
The portfolio is heavily concentrated in health care, which increases the risk if this single sector faces a downturn.
Limited Geographic Diversification
Almost all holdings are in U.S. companies, offering little protection if the U.S. market or regulatory environment for health care weakens.
Moderately High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which can gradually reduce net returns for long-term investors.
LFSC vs. SPDR S&P 500 ETF (SPY)
AUM102.42M
RegionNorth America
Expense Ratio0.54%
Beta1.12
IssuerF/m
Inception DateOct 30, 2024
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,843
30 Day Avg. Volume4,446
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
57.61Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering40
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LFSC Summary
The F/M Emerald Life Sciences Innovation ETF (LFSC) focuses on innovative health care companies, mainly in pharmaceuticals, biotechnology, and life sciences, rather than tracking a traditional index. It invests mostly in U.S. firms working on new drugs, medical treatments, and health technologies, including names like United Therapeutics and Guardant Health. Someone might consider this ETF if they want targeted exposure to potential growth in cutting-edge medical breakthroughs and to diversify beyond broad market funds. However, it is heavily concentrated in a single sector, so its price can be very volatile and may rise or fall sharply with health care and biotech news.
How much will it cost me?The F/M Emerald Life Sciences Innovation ETF (LFSC) has an expense ratio of 0.54%, meaning you’ll pay $5.40 per year for every $1,000 invested. This is slightly higher than average because it’s actively managed, focusing on specialized companies in the Pharma, Biotech & Life Sciences sector to capture unique growth opportunities.
What would affect this ETF?The LFSC ETF, focused on U.S.-based pharmaceutical, biotech, and life sciences companies, could benefit from advancements in medical technology, increased healthcare spending, and favorable regulatory approvals for new treatments. However, it may face challenges from rising interest rates, which can impact funding for innovation, and regulatory hurdles that could delay drug approvals or increase costs for its top holdings. Economic downturns or reduced government healthcare budgets could also negatively affect the sector.
LFSC Top 10 Holdings
LFSC is a high-conviction bet on U.S. biotech and life sciences, with performance driven by a handful of volatile innovators. Spyre Therapeutics has been the fund’s rocket ship lately, rising sharply and giving the portfolio a strong growth engine, while Nektar Therapeutics and KalVista are also adding fuel with improving momentum despite shaky finances. United Therapeutics provides a steadier, profitable anchor amid all the clinical-stage risk. On the flip side, Guardant Health and TransMedics have been losing steam recently, quietly tugging on returns in this otherwise aggressively growth-focused health care basket.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Cogent Biosciences | 7.52% | $7.71M | $5.58B | 569.67% | 37 Underperform | |
| Travere Therapeutics | 7.25% | $7.43M | $3.96B | 153.51% | 56 Neutral | |
| LivaNova | 6.92% | $7.09M | $3.85B | 57.66% | 63 Neutral | |
| Spyre Therapeutics | 6.83% | $7.00M | $6.51B | 398.35% | 43 Neutral | |
| Mirum Pharmaceuticals | 5.27% | $5.41M | $6.23B | 127.03% | 56 Neutral | |
| United Therapeutics | 4.36% | $4.47M | $24.13B | 86.20% | 79 Outperform | |
| Guardant Health | 4.22% | $4.32M | $12.59B | 133.39% | 61 Neutral | |
| Nektar Therapeutics | 3.91% | $4.00M | $2.39B | 587.30% | 47 Neutral | |
| Veradermics, Incorporated | 3.75% | $3.85M | ― | ― | ― | |
| Trevi Therapeutics | 3.36% | $3.45M | $2.02B | 118.46% | 55 Neutral |
LFSC Technical Analysis
Neutral
―
Price Trends
36.25
Positive
36.28
Positive
33.78
Positive
Market Momentum
0.33
Positive
42.37
Neutral
9.63
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For LFSC, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 37.98, equal to the 50-day MA of 36.25, and equal to the 200-day MA of 33.78, indicating a neutral trend. The MACD of 0.33 indicates Positive momentum. The RSI at 42.37 is Neutral, neither overbought nor oversold. The STOCH value of 9.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LFSC.
LFSC Peer Comparison
Comparison Results
Performance Comparison
LFSC
F/M Emerald Life Sciences Innovation ETF
36.66
13.16
56.00%
CHPY
YieldMax Semiconductor Portfolio Option Income ETF
―
―
―
IETC
iShares Evolved US Technology ETF
―
―
―
GTOP
Goldman Sachs Technology Opportunities ETF
―
―
―
FEPI
REX FANG & Innovation Equity Premium Income ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents